Emerging pharmacologic treatment options for fragile X syndrome

Por Schaefer, Tori L, Davenport, Matthew H, Erickson, Craig A
Publicado no Appl Clin Genet (2015)

Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety

Por Schaefer, Tori L., Davenport, Matthew H., Grainger, Lindsay M., Robinson, Chandler K., Earnheart, Anthony T., Stegman, Melinda S., Lang, Anna L., Ashworth, Amy A., Molinaro, Gemma, Huber, Kimberly M., Erickson, Craig A.
Publicado no J Neurodev Disord (2017)

Fragile X targeted pharmacotherapy: lessons learned and future directions

Por Erickson, Craig A., Davenport, Matthew H., Schaefer, Tori L., Wink, Logan K., Pedapati, Ernest V., Sweeney, John A., Fitzpatrick, Sarah E., Brown, W. Ted, Budimirovic, Dejan, Hagerman, Randi J., Hessl, David, Kaufmann, Walter E., Berry-Kravis, Elizabeth
Publicado no J Neurodev Disord (2017)